ANIPのニュース
ANI Pharmaceuticals: Strong Revenue Growth And ANDA Approvals 2023/05/31 01:12:20 Seeking Alpha
ANI Pharmaceuticals exceeded Q1 Non-GAAP earnings expectations and raised its guidance to $385-$410 million. See why I rate ANIP stock a Strong Buy here.
Looking Into ANI Pharmaceuticals''s Return On Capital Employed 2023/05/23 14:47:40 Benzinga
According to Benzinga Pro, during Q1, ANI Pharmaceuticals (NASDAQ: ANIP ) earned $1.44 million, a 133.91% increase from the preceding quarter. ANI Pharmaceuticals also posted a total of $106.79 million in sales, a 13.32% increase since Q4. In Q4, ANI Pharmaceuticals brought in $94.23 million in sales but lost $4.24 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative … Full story available on Benzinga.com
ANI Pharma Says FDA Approves Methsuximide Capsules, Alendronate Sodium Oral Solution 2023/05/15 11:28:14 RTT News
ANI Pharmaceuticals, Inc. (ANIP) announced Monday that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Applications (ANDAs) for Methsuximide Capsules USP, 300 mg and Alendronate Sodium Oral Solution 70 mg (base)/75 mL.
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity 2023/05/15 10:50:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Applications (ANDAs) for Methsuximide Capsules USP, 300 mg and Alendronate Sodium Oral Solution 70 mg (base)/75 mL. Methsuximide Capsules has been granted 180-day Competitive Generic Therapy (CGT) Exclusivity, and Alendronate Sodium Oral Solution is eligible for CGT Exclusivity upon launch.
ANI Pharmaceuticals (NASDAQ:ANIP) Rating Increased to Buy at StockNews.com 2023/05/14 07:38:31 EIN News Pharmaceuticals
… (Get Rating) ANI Pharmaceuticals , Inc is a bio- pharmaceutical company, which engages … marketing branded and generic prescription pharmaceuticals . Its areas of product development … '' ratings for ANI Pharmaceuticals and related companies with MarketBeat …
Earnings Preview For ANI Pharmaceuticals 2023/05/05 19:02:41 Benzinga
ANI Pharmaceuticals (NASDAQ: ANIP ) is set to give its latest quarterly earnings report on Monday, 2023-05-08. Here''s what investors need to know before the announcement. Analysts estimate that ANI Pharmaceuticals will report an earnings per share (EPS) of $0.35. ANI Pharmaceuticals bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
ANI Pharmaceuticals Q1 2023 Earnings Preview 2023/05/05 16:17:17 Seeking Alpha
ANI Pharmaceuticals (ANIP) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open.The consensus EPS Estimate is $0.35 (+391.7% Y/Y) and the consensus…
ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET 2023/04/27 10:50:00 Business Wire
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2023 financial resul
ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ 2023/04/26 20:15:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ Headquarters in New York City as follows: Date: Tuesday, May 2, 2023 Time: 12:00 p.m. ET Webcast: Click Here The webcast will be accessible on demand beginning on M
ANI Pharma Soars on FDA Approval for Furadantin Generic Version 2023/04/24 11:55:30 TipRanks
Shares of biopharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) are soaring higher today after the U.S. Food and Drug Administration (FDA) ap…
ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET 2023/04/27 10:50:00 Business Wire
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2023 financial resul
ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ 2023/04/26 20:15:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ Headquarters in New York City as follows: Date: Tuesday, May 2, 2023 Time: 12:00 p.m. ET Webcast: Click Here The webcast will be accessible on demand beginning on M
ANI Pharma Soars on FDA Approval for Furadantin Generic Version 2023/04/24 11:55:30 TipRanks
Shares of biopharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) are soaring higher today after the U.S. Food and Drug Administration (FDA) ap…
ANI Pharmaceuticals stock rises after FDA approval of generic antibiotic 2023/04/24 11:30:10 Seeking Alpha
ANI Pharmaceuticals (ANIP) said the U.S. FDA approved its generic antibacterial medicine Nitrofurantoin Oral Suspension. Read more here
ANI Pharma: FDA Approves ANDA For Nitrofurantoin Oral Suspension USP 2023/04/24 11:24:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) announced Monday that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application or ANDA for Nitrofuran…